← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $618B	4,661	+110	+2%	$432B
2	2 AbbVie ABBV $506B	4,117	-56	-1%	$282B
3	3 Merck MRK $363B	3,811	+138	+4%	$232B
4	4 Amgen AMGN $237B	3,152	+54	+2%	$155B
5	5 Pfizer PFE $169B	2,964	+41	+1%	$106B
6	6 Bristol-Myers Squibb BMY $125B	2,544	+81	+3%	$98.1B
7	7 Gilead Sciences GILD $194B	2,331	+104	+5%	$152B
8	8 Novartis NVS $288B	1,604	+89	+6%	$22B
9	9 Regeneron Pharmaceuticals REGN $82.2B	1,400	+10	+0.7%	$69.8B
10	10 AstraZeneca AZN $259B	1,385	-24	-2%	$152B
11	11 GSK GSK $99.7B	1,038	+40	+4%	$20.7B
12	12 Incyte INCY $23.2B	815	-8	-1%	$19.2B
13	13 Natera NTRA $56.2B	767	-19	-2%	$26.5B
14	14 Exelixis EXEL $15.5B	701	+16	+2%	$11.1B
15	15 Halozyme HALO $13.8B	637	+18	+3%	$7.79B
16	16 Jazz Pharmaceuticals JAZZ $13.7B	577	+1	+0.2%	$12.3B
17	17 Revolution Medicines RVMD $38.7B	514	+128	+33%	$19.1B
18	18 Guardant Health GH $21.3B	486	-11	-2%	$12.5B
19	19 Tempus AI TEM $12B	427	-30	-7%	$4.75B
20	20 Lantheus LNTH $6.53B	408	+15	+4%	$5.51B
21	21 ImmunityBio IBRX $10B	386	+108	+39%	$1.36B
22	22 Takeda Pharmaceutical TAK $62.9B	362	+12	+3%	$1.82B
23	23 Qiagen QGEN $9.52B	346	+24	+7%	$5.02B
24	24 Recursion Pharmaceuticals RXRX $2.02B	335	+1	+0.3%	$1.03B
25	25 Veracyte VCYT $3.48B	334	+5	+2%	$2.84B